2. Academic Validation
  3. Design and Discovery of New Collagen V-Derived FGF2-Blocking Natural Peptides Inhibiting Lung Squamous Cell Carcinoma In Vitro and In Vivo

Design and Discovery of New Collagen V-Derived FGF2-Blocking Natural Peptides Inhibiting Lung Squamous Cell Carcinoma In Vitro and In Vivo

  • J Med Chem. 2024 Aug 8;67(15):12660-12675. doi: 10.1021/acs.jmedchem.4c00654.
Keli Kuang 1,  Xiang Chen 1,  Maolin Wang 1,  Weijing Han 2,  Xue Qiu 3 4,  Taoli Jin 2,  Rong Xu 2,  Bing Yuan 2,  Meiqi Qian 3 4,  Chunyan Li 1,  Run Xiang 5,  Fei Li 1,  Shuwen Zhang 1,  Zi Yang 1,  Junrong Du 1,  Dapeng Li 1,  Chun Zhang 1,  Qiantao Wang 1,  Tao Jia 1
Affiliations

Affiliations

  • 1 Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
  • 2 Songshan Lake Materials Laboratory, Dongguan, Guangdong 523808, China.
  • 3 Key Laboratory of Marine Drug, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
  • 4 Laboratory forMarine Drugs and Bioproducts, Qingdao National Laboratory for Marine Scienceand Technology, Ocean University of China, Qingdao 266237, China.
  • 5 Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China.
PMID: 39045829 DOI: 10.1021/acs.jmedchem.4c00654
Abstract

Aberrant FGF2/FGFR signaling is implicated in lung squamous cell carcinoma (LSCC), posing treatment challenges due to the lack of targeted therapeutic options. Designing drugs that block FGF2 signaling presents a promising strategy different from traditional kinase inhibitors. We previously reported a ColVα1-derived fragment, HEPV (127AA), that inhibits FGF2-induced angiogenesis. However, its large size may limit therapeutic application. This study combines rational peptide design, molecular dynamics simulations, knowledge-based prediction, and GUV and FRET assays to identify smaller Peptides with FGF2-blocking properties. We synthesized two novel Peptides, HBS-P1 (45AA) and HBS-P2 (66AA), that retained the heparin-binding site. Both Peptides demonstrated anti-LSCC and antiangiogenesis properties in cell viability and microvessel network induction assays. In two LSCC subcutaneous models, HBS-P1, with its affinity for FGF2 and enhanced penetration ability, demonstrated substantial therapeutic potential without apparent toxicities. Our study provides the first evidence supporting the development of collagen V-derived natural Peptides as FGF2-blocking agents for LSCC treatment.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z